



Influenza antiserum reagent 17/132 is prepared in sheep for single radial diffusion assay of A/Egypt/N04915/2014 antigens. An appropriate NIBSC reagent should be included in each assay

CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom.

The antiserum reagent was prepared in sheep SH672 and sheep SH673 to the purified HA of NIBRG-306 (a reassortant prepared by reverse genetics with HA and NA from A/Egypt/N04915/2014 H5N1 virus). The HA antigen was extracted from purified virus by treatment with bromelain and purified by sedimentation on sucrose gradients (Brand, CN and Skehel, JJ, Nature, New Biology, 1972, 238, 145-147.

The immunisation schedule for sheep SH672 and SH673 was as follows: One dose of approximately 50 micrograms of HA with Freund's Complete Adjuvant was given intramuscularly, followed two weeks later with an approximate 10 microgram dose of HA with Freund's Incomplete Adjuvant (FIA), six further approximate 10 microgram doses of HA with FIA were given at weekly intervals. Ten weeks after the initial immunisation, serum was collected and sodium azide (0.05% w/v) was added.

The serum was treated by maintenance of pH5.5 (or lower) for 30 minutes followed by restoration of the original pH. The serum from SH672 and SH673 was pooled and then diluted with phosphate buffered saline containing sodium azide (0.05% $\mbox{w/v})$ and filled into vials in 2ml volumes.

5. STORAGE

+2-8°C

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

Vials have a 'flip-up' circular cap. Either on the cap or the collar of the vial, there is an indication of the point at which to lever off the cap. This exposes an area of the stopper through which reconstitution and withdrawal of the preparation can be made using a hypodermic needle and syringe. If use of a pipette is preferred, then fully remove the metal collar using, for example, forceps, taking care to avoid cuts by wearing appropriate gloves. Remove the stopper for access. Care should be taken to prevent loss of the contents.

USE OF MATERIAL

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards,

UK Official Medicines Control Laboratory



For the assay of antigens containing 20-50 micrograms of HA activity in 1ml, approximately 20µl of the undiluted Reagent should be added to 1ml agarose. It may be necessary to change the antiserum concentrations according to local laboratory conditions.

Antiserum Reagent 17/132 should be used according to the method described by Wood, JM, Schild, GC, Newman, RW and Seagroatt, VA. Journal of Biological Standardisation, 1977, 5, 237-247.

8. STABILITY

Reference materials are held at NIBSC within assured, temperaturecontrolled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

REFERENCES 9.

N/A

10. **ACKNOWLEDGEMENTS**

N/A

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials:

http://www.bipm.org/en/committees/jc/jctlm/

Derivation of International Units:

http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC:

http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:

http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC)

No 1272/2008: Not applicable or not classified				
Physical and Chemical properties				
Physical appearance: straw coloured liquid		Corrosive:	No	
Stable: Yes		Oxidising:	No	
Hygroscopic: No		Irritant:	No	
Flammable: No		Handling:See	caution, Section 2	
Other (specify): Contains sheep serum and sodium azide				
Toxicological properties				
Effects of inhalation: Not		established, avoid inhalation		
Effects of ingestion: Not		established, avoid ingestion		
Effects of skin absorption: Not		established, avoid contact with skin		





Suggested First Aid		
Inhalation:	Seek medical advice	
Ingestion:	Seek medical advice	
Contact with eyes:	Wash with copious amounts of water. Seek medical advice	
Contact with skin:	Wash thoroughly with water.	

Action on Spillage and Method of Disposal

Spillage of contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water.

Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: 2g

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: Yes Vet certificates. Plus FMD Inactivation Certificates and Storage Information sheet.





STORAGE OF REAGENT 17/132

NIBSC has prepared a number of reagents for single radial diffusion assay of influenza subtypes of pandemic potential.

Since it is not known when these reagents may be required, it is desirable that they have an indefinite shelf life and they are stored at NIBSC in colder conditions than reagents prepared for the assay of epidemic strains. Therefore the recommended storage temperature marked on the label for reagent 17/132 is -20°C.

However it is assumed that a customer ordering this reagent, will use it within a short period similar to that for a conventional reagent. Consequently, this reagent is not normally shipped frozen and <u>the recommended</u> storage temperature is $+4^{\circ}C$.





Arturo Fernandez DVM MRCVS
Named Veterinary Surgeon
Royal Veterinary College
Royal College Street
LONDON
NW1 0TU

VETERINARY CERTIFICATE OF ANIMAL HEALTH

This is to certify that I have examined a Sheep with ear tag number: UK 0101954 00993 [Virology no. SH672], which has been used in the production of blood antiserum between 1st March 2017 and 9st May 2017. Both the ear tag number and the animals' record show that it is of UK origin.

This animal was a breeding Ewe which became surplus to requirements. In my opinion at the time of clinical examination, the ewe was in good health and showed no clinical signs of infectious disease.

Arturo Fernandez DVM MRCVS Named Veterinary Surgeon

Arturo Fernandez DVM MRCVS
Named Veterinary Surgeons (NVS) Group
The Royal Veterinary College, Royal College Street, London NW1 0TU
Mobile: 07733 103881, E-mail: arfernandez@rvc.ac.uk





Arturo Fernandez DVM MRCVS
Named Veterinary Surgeon
Royal Veterinary College
Royal College Street
LONDON
NW1 0TU

VETERINARY CERTIFICATE OF ANIMAL HEALTH

This is to certify that I have examined a Sheep with ear tag number: UK 0101972 00217 [Virology no. SH673], which has been used in the production of blood antiserum between 1st March 2017 and 9th May 2017. Both the ear tag number and the animals' record show that it is of UK origin.

This animal was a breeding Ewe which became surplus to requirements. In my opinion at the time of clinical examination, the ewe was in good health and showed no clinical signs of infectious disease.

Arturo Fernandez DVM MRCVS Named Veterinary Surgeon

Arturo Fernandez DVM MRCVS
Named Veterinary Surgeons (NVS) Group
The Royal Veterinary College, Royal College Street, London NW1 0TU
Mobile: 07733 103881, E-mail: arfernandez@rvc.ac.uk







Foot and Mouth Disease Virus Inactivation Certificate

This is to certify that serum collected from Sheep no. 0101954 00993 [Virology nos.SH672] has been treated by an APHIS approved method for inactivation of Foot and Mouth Disease Virus. The treatment method used was maintenance of pH5.5 or lower for a minimum of 30 minutes.

28.3.18

Dr Nicola Rose

Acting Head of Viral Vaccines

Division of Virology

National Institute for Biological Standards and Control







Foot and Mouth Disease Virus Inactivation Certificate

This is to certify that serum collected from Sheep no. 0101972 00217 [Virology nos.SH673] has been treated by an APHIS approved method for inactivation of Foot and Mouth Disease Virus. The treatment method used was maintenance of pH5.5 or lower for a minimum of 30 minutes.

28-3.18

Dr Nicola Rose Acting Head of Viral Vaccines

Division of Virology

National Institute for Biological Standards and Control